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Background: This study is done to compare the effect of adjunctive therapy with pregabalin versus usual care (UC)
on health-care costs and clinical and patients consequences in generalized anxiety disorder (GAD) subjects with
partial response (PR) to a previous selective serotonin reuptake inhibitor (SSRI) course in medical practice in Spain.
Methods: Post hoc analysis of patients with PR to SSRI monotherapy enrolled in a prospective 6-month naturalistic
study was done. PR was defined as a Clinical Global Impression (CGI) scale score ≥3 and insufficient response with
persistence of anxiety symptoms ≥16 in the Hamilton Anxiety Rating Scale (HAM-A). Two groups were analyzed: 1)
adjunctive therapy (AT) with pregabalin (150–600 mg/day) to existing therapy and 2) UC (switching to a different
SSRI or adding another anxiolytic different than pregabalin). Costs included GAD-related health-care resources
utilization. Consequences were a combination of psychiatrist-based measurements [HAM-A, CGI, and Montgomery-Asberg
Depression Rating Scale (MADRS)] and patient-reported outcomes [Medical Outcomes Study Sleep (MOS-sleep) scale,
disability (World Health Organization Disability Assessment Schedule II (WHO-DAS II) and quality-of-life (Euro Qol-5D
(EQ-5D)]. Changes in both health-care costs and scale scores were compared separately at end-of-trial visit by a general
linear model with covariates.
Results: Four hundred eighty-six newly prescribed pregabalin and 239 UC GAD patients [mean (SD) HAM-A 26.7 (6.9)
and CGI 4.1 (0.5)] were analyzed. Adding pregabalin was associated with significantly higher mean (95% CI) score
reductions vs. UC in HAM-A [−14.9 (−15.6; −14.2) vs. −11.2 (−12.2; −10.2), p < 0.001] and MADRS [−11.6 (−12.2; −10.9)
vs. −7.8 (−8.7; −6.8), p < 0.001]. Changes in all patient-reported outcomes favored significantly patients receiving
pregabalin, including quality-of-life gain; 26.4 (24.7; 28.1) vs. 19.4 (17.1; 21.6) in the EQ-VAS, p < 0.001. Health-care
costs were significantly reduced in both cohorts yielding similar 6-month costs; €1,565 (1,426; 1,703) pregabalin and
€1,406 (1,200; 1,611) UC, p = 0.777. The effect of sex on costs and consequences were negligible.
Conclusion: In medical practice, GAD patients with PR to SSRI experienced greater consequence improvements
with adjunctive therapy with pregabalin versus UC, without increasing health-care cost. The effect of pregabalin was
independent of patient gender.
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Generalized anxiety disorder (GAD) is one of the most
frequent mental disorders [1-3]. GAD is characterized
by a chronic evolution with a relatively late-onset age
(31 years as a median age) [4]. The prevalence of GAD
in western societies ranges from 2.8% in Europe to 5.7%
in the United States. Specifically and according to a large
epidemiological report, the prevalence of GAD in Spain
has been estimated to be 2% [5]. The recent existing
limitations on economic resources highlight the import-
ance of their optimal utilization and the efficient cost-
consequence analysis of new treatments by health policy
decision makers. The most appropriate and useful method
for the estimation of economic consequences in the man-
agement of anxiety disorders is the economic analysis that
take into account both the overall health-care resource
costs and the acquisition cost of the prescribed drugs [6].
For anxiety disorders, their considerable chronicity of
symptoms, associated comorbidities and involved phys-
ical limitations, constitute a scenario that clearly deter-
mines an important impact on work productivity as well
as high medical resource use by patients. As a conse-
quence, the economic burden of GAD in current health
systems has been evaluated as highly significant [7,8].
Specifically in Spain, the gross annual direct cost of
GAD has been estimated as €2 million in a total popula-
tion of 3,014 patients. Half of these total direct costs
were associated with prescription drugs, but the total
figure includes also physical services, laboratory analysis,
and fixed costs [9]. Otherwise, overall economic costs of
GAD in Spain are still scarce and have not been evalu-
ated until very recently [10]. Frequently, the most com-
mon psychoactive drugs used in the management of
GAD were anxiolytics. Within the most prescribed anxi-
olytics, benzodiazepines have been proved both effica-
cious and rapid for the treatment of GAD patients [11].
Nonetheless, recent guidelines recommend the use of
benzodiazepines in a short-term period in response to
some limitations that have been observed such as their
associated comorbidity of depressive symptoms and
common adverse events like sedation; memory and psy-
chomotor dysfunction; increase in abuse, tolerance, or
dependence; and afflictive withdrawal symptomatology
[12-16]. Accordingly, the Spanish Health Ministry guide-
lines recommended the use of benzodiazepines for a re-
stricted period not longer than 2–4 weeks [17].
When considering a long-term approach therapy,
GAD effective treatment should be focused on select-
ive serotonin reuptake inhibitors (SSRIs), selective
serotonin-norepinephrine reuptake inhibitors (SNRIs),
and pregabalin as a first choice according to current
European guidelines [18]. Besides the delayed onset of
SSRI/SNRI therapeutic effect [18], other disadvantages
include the fact that their use in monotherapy iscontraindicated in GAD patients diagnosed with co-
morbid bipolar disorder [19-21]. On the other hand
and despite potential misuse and abuse of pregabalin
pointed out by some researchers [22,23], pregabalin
has been proven effective and well-tolerated as a long-term
therapy option in adult patients with GAD [24,25], and, as
mentioned previously, it is recommended as a first choice
in the therapy of GAD by European guidelines [18].
Pregabalin acts as a calcium channel modulator that allows
a relatively rapid onset of action after only 1 week, as well
as a similar efficacy with that of benzodiazepines and a
lower rate of discontinuation than that of benzodiazepines
and SNRIs [26,27].
Current health-care resource utilization and related
costs may differ depending on both the exact therapies
and health-care settings. It is important to consider clin-
ical practice to attain a real-world framework which
could differ extensively from clinical trial observations
[28]. Focusing on daily clinical practice needs, the aim of
this study was to compare the effect of adjunctive ther-
apy (AT) with pregabalin versus usual care (UC) on
health-care costs and clinical and patients consequences
in GAD subjects with partial response (PR) to a previous
SSRI course in medical practice in Spain.
Methods
Study design
This is a post hoc economic analysis based on data from
a previous 6-month, multicenter, prospective observa-
tional study: the Amplification of Definition of Anxiety
(ADAN) study carried out between October 2007 and
January 2009 in outpatient mental health centers in
Spain [29]. The ADAN study was designed to elucidate
the effect of broadening DSM-IV criteria for GAD and
was approved by the local ethics committee of the Hos-
pital Clínico de San Carlos (Madrid). It was conducted
according to the Helsinki Declaration for research in the
human being. Due to the observational design of the
study, only two visits (baseline and 6 months visit) were
planned. The ADAN study also assessed the use of
health-care resources and related costs, which were used
for the present cost analysis to compare the impact of
initiating treatment with pregabalin versus usual care.
Study population
In the ADAN study, trained psychiatrists, with at least
5 years experience in mental health diseases diagnosis,
were asked to select consecutive, newly diagnosed GAD
patients, according to DSM-IV criteria (APA 2000) and
so-called broad criteria, until the predetermined sample
size was obtained [29]. Patients of both sex, aged 18 or
above, who had provided their written informed consent
to participate in the study, and with partial response to
SSRI monotherapy were considered eligible for inclusion.
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a benzodiazepine at standard doses. Partial response was
defined as an insufficient response with persistence of
anxiety symptoms >16 in the Hamilton Anxiety Rating
Scale (HAM-A) [30,31] and a Clinical Global Impression
scale score >3 determined at baseline visit [32]. Exclusion
criteria included previous GAD diagnosis, inability or diffi-
culty to understand patient-reported outcomes question-
naires written in Spanish, a score ≤9 point in the HAM-A
scale and a score >35 in the Montgomery-Asberg Depres-
sion Rating Scale. In this analysis, only patients with a
diagnosis of GAD according to DSM-IV criteria were
considered eligible. Two groups (based on psychiatrist judg-
ment) were analyzed: 1) adding pregabalin (150–600 mg/
day) to existing therapy and 2) usual care (switching to a
different SSRI and/or adding another anxiolytic different
than pregabalin).
Use of health-care resources and cost estimation
Health-care resource utilization associated with GAD
during the previous 6-month period was retrospectively
collected at baseline and at the 6-month study visit, by
means of a case report form which was designed ad hoc
for this economic analysis. Health-care resource utilization
included the following: drug utilization, medical visits and
hospitalizations (from patients’ medical records), and non-
pharmacological treatments (recorded during patient in-
terviews). No records of diagnostic tests were registered
since this variable was considered negligible in GAD. Four
categories of health-care resources utilization were estab-
lished: drug treatments, non-pharmacological therapies,
medical visits (psychiatrists, psychologists, general practi-
tioner or family physicians, and emergency room visits),
and days of hospitalization in psychiatry or internal medi-
cine wards. Non-pharmacological therapies included all
those treatments used in clinical practice as complemen-
tary/adjuvant (psychosocial therapy, cognitive-conductive
therapy, supportive groups, and relaxation sessions) to
drug treatments for GAD. Visits to primary care, emer-
gency department, psychologist, and psychiatrist were re-
corded under the category “medical visits”.
Costs estimation used year 2012 prices for GAD-
related health-care resources utilization under the per-
spective of the Spanish National Health System. The
costs of drugs were estimated using retail price + taxes
of the cheapest generic medication or reference price
from the Spanish Pharmaceutical Drug Catalogue of
2012. The cost of non-pharmacological treatments, med-
ical visits, and hospitalizations was obtained from the
eSALUD health-care costs database for 2012 [33] up-
dated with the 2012 health-care inflation rate [34].
Finally, some non-pharmacological resources were priced
according to expert opinion and/or directly from the
vendor/provider. The direct mean cost at baseline and atthe 6-month visit and change from baseline was calculated
by multiplying the number of resources used in each
period by their respective prices.Clinical and patients consequences
Consequences in this study were a health profile based
in the combination of psychiatrist-based measure-
ments [Hamilton Anxiety Rating Scale, Clinical Global
Impression-Improvement (CGI-I) scale, and Montgomery-
Asberg Depression Rating Scale (MADRS)], and patient-
reported-outcomes [Medical Outcomes Study Sleep
(MOS-sleep) scale, disability (The World Health
Organization Disability Assessment Schedule II (WHO-
DAS II)) and quality-of-life (Euro Qol-5D (EQ-5D))]
[31,35-39]. The Hamilton Anxiety Rating Scale is a 14-
item scale, each with a score between 0 (absence) and 4
(severe) that explores the patients’ degree of anxiety and
that includes two subscales, one for psychic symptoms
and the other for somatic symptoms [40]. The CGI-I scale
is a seven-point scale that evaluates the clinician’s assess-
ment on how much the patient’s illness has improved or
worsened relative to a baseline state [35]. The MADRS is
a ten-item diagnostic questionnaire which psychiatrists
use to measure the severity of depressive episodes in pa-
tients with mood disorders [36]. The MOS-sleep scale
measures the global subjective sleep disturbance per-
ceived by the patient based on six dimensions of sleep
[37]. It consists of 12 items which form six subscales
or domains: sleep disturbance, snoring, awakening
with shortness of breath or headache, adequacy of sleep,
daily somnolence, and sleep quantity. In addition, the
MOS-sleep scale provides a summary index of sleep prob-
lems through the scores of 9 of its items: the higher the
score, the worse the sleep. WHO-DAS II is a disability in-
strument designed based on the ICF framework, assessing
six domains of functioning in daily life [38]. The WHO-
DAS II is a standardized measurement of disability for use
in diverse cultural settings, translated into 16 languages to
date. The WHO-DAS II domains include understanding
and communicating, getting around, self-care, getting
along with others, life activities, and participation in soci-
ety. The EQ-5D is a standardized health-related quality of
life and is a generic self-reported measure of health used
frequently in clinical and economic evaluations [39]. In
this five-item generic measurement of health state, the de-
gree of impairment is assessed in five domains: mobility,
self-care, daily activities, pain/discomfort, and anxiety/de-
pression. The scores of the five items may be used to cal-
culate a utility index, or social tariff, in the range of −0.6
through 1.0, where the higher scores represent a better
health state. This instrument also includes a 20-cm visual
analog scale (EQ-VAS) ranging from 0 = worst imaginable
health state through 100 = best imaginable health state.
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Only patients that fulfilled all inclusion criteria and none
of the exclusion criteria were included in the statistical
analysis. Descriptive statistics were completed for the
continuous variables in the study, including the assess-
ment of central tendency and dispersion statistics with its
95% confidence interval when possible. The Kolmogorov-
Smirnov test was applied to check adjustment of data to a
Gaussian distribution. For categorical variables, absolute
and relative frequencies were calculated. A descriptive
statistical analysis with values for mean and standard
deviation (SD) was performed. Mann-Whitney U-test was
used to compare continuous variables between the two
groups of patients at baseline, while the χ2-test or the
Fisher’s exact test were applied for categorical data. Differ-
ences in the use of health-care resources and costs
between the two treatment groups were tested using an
analysis of covariance (ANCOVA), according to the pub-
lished recommendations [41] with sex, age, and baseline
values as covariates. The change from baseline for quanti-
tative variables was calculated as the final value minus
baseline value and is presented as the mean value and its
95% confidence interval (CI). Adjusted changes both in
health-care costs and scale scores were compared at
end-of-trial visit by a general linear model with covari-
ates. A p value of less than 0.05 was considered signifi-
cant. Data analysis was performed using the Statistical
Analysis System (SAS 9.1).
Results
Patient disposition and baseline characteristics
A total of 725 subjects were included in this sub-analysis
sample: 486 newly prescribed pregabalin and 239 UC
GAD patients [mean (SD) HAM-A 26.7 (6.9) and CGI
4.1 (0.5)]. The two study groups were well balanced with
respect to demographic characteristics at baseline
(Table 1). Mean age per group was 47.0 (12.6) years in
the pregabalin group and 45.2 (13.6) years in the UC
group. Percentage of women (72.9% and 69.1%, respect-
ively) and work active subjects (51.8% and 49.8%, re-
spectively) were similar in both groups. Subjects in the
pregabalin group showed higher mean baseline scores of
HAM-A (27.2 ± 6.6 points vs. 25.7 ± 7.2 points in the
UC group; p = 0.015), as well as of MADRS (23.6 ± 6.9
points vs. 21.7 ± 7.5 points, respectively, p < 0.001).
Psychiatrists’ clinical impression (CGI) was also higher
in the pregabalin group: 4.23 ± 0.76 vs. 3.97 ± 0.79
(p = 0.000).
Anxiety and depression outcomes
Adding pregabalin was associated with significantly
higher benefit in anxiety and depression outcomes, as
reflected by mean (95% CI) reduction vs. UC in HAM-A
[−15.2 (−16.0; −14.4) vs. −10.7 (−11.8; −9.5), p < 0.001]and MADRS [−11.8 (−12.5; −11.1) vs. −7.3 (−8.3; −6.3),
p < 0.001] (Figure 1). No significant differences between
sexes were observed in the reduction of these variables.
Similarly, the change in CGI-I scale presented significant
differences between groups: −1.7 in pregabalin vs. −1.2
in UC (p < 0.005). Figure 2 shows in detail the specific
changes in the 14 anxiety-related items included in the
HAM-A. Reductions in all items favored the pregabalin
group with statistically significant differences for anxious
mood (p < 0.05), tension (p < 0.05), fears (p < 0.05), intel-
lectual (p < 0.001), somatic (sensory) (p < 0.01), gastro-
intestinal (p < 0.05), and autonomic symptoms (p < 0.05).Patient-reported outcomes
As shown in Table 2, adjusted significant changes be-
tween visits were observed in all patient-reported out-
comes. The detected improvements in sleep problems
measured by the MOS-sleep scale (Table 2) and WHO-
DAS II disability scale (Figure 3) favored differentially to
patients in the group receiving pregabalin. Mean reduc-
tion (±95% CI) in general index sleep problems of the
MOS-sleep scale was 26.4 (24.7, 28.1) in the pregabalin
group and 19.6 (17.3, 22.0) in the UC group (p < 0.001).
All items of the MOS-sleep scale reflected reductions
that significantly favored the pregabalin group, except
the snoring item and the optimal sleep score that
accounted for non-significant lower reductions in pa-
tients treated with pregabalin (Table 2).
Likewise, Figure 3 depicts the mean adjusted reduction
in WHO-DAS II disability scale domains. All disability
domains presented significant differences between
groups in the score reduction at the final visit. The glo-
bal WHO-DAS II changes for employed patients (seven
domains) was −21.7 (−23.3, −20.1) in the pregabalin
group and −15.3 (−17.5, −13.1) in the UC group (p <
0.0001), while mean reductions for unemployed patients
(six domains) were calculated as −20.6 (−22.2, −19.1) in
the pregabalin group and −14.7 (−16.7, −12.5) in the UC
group (p < 0.0001).Quality of life
At the end of the study, changes in the majority of
quality-of-life outcomes also favored significantly to pa-
tients receiving pregabalin, except for the mobility and
personal care items where the differences were not sig-
nificant (Table 2). Global health status estimated by the
social tariff reflected a mean improvement of 0.36 (0.34,
0.38) for pregabalin patients and 0.29 (0.26, 0.33) for UC
patients (p < 0.001) after 6 months of the study initiation.
The patient’s self-assessed quality of life calculated after
visual analog scale completion also shown a significant
better improvement for pregabalin patients: 26.4 (24.7,
28.1) vs. 19.4 (17.1, 21.6) (p < 0.001).
Table 1 Demographic and baseline clinical characteristics
of patients
Characteristic Pregabalin Usual care p
N = 486 N = 239
Age (years), mean (SD) 47.0 (12.6) 45.2 (13.6) 0.070
Sex (female), n (%) 325 (72.9%) 159 (69.1%) 0.307
Body mass index (kg/m2), mean (SD) 25.6 (4.0) 26.1 (4.7) 0.185
Marital status, n (%) 0.625
Married or with couple 307 (63.2%) 154 (65.0%)
Single 105 (21.6%) 57 (24.1%)
Widow/er 25 (5.1%) 9 (3.8%)
Divorced/separated 49 (10.1%) 17 (7.2%)
Educational level, n (%) 0.463
No education 15 (3.1%) 15 (6.3%)
Primary education 183 (37.7%) 85 (35.6%)
Secondary education 106 (21.9%) 48 (20.1%)
Intermediate educational level 102 (21.0%) 46 (19.3%)
Higher education (university) 75 (15.5%) 43 (18.0%)
Others 4 (0.8%) 2 (0.8%)
Work status, n (%) 0.219
Active 251 (51.8%) 119 (49.8%)
Housewife 127 (26.2%) 58 (24.3%)
Sick leave 47 (9.7%) 11 (4.6%)
Unemployed 32 (6.6%) 18 (7.5%)
Retired 19 (3.9%) 20 (8.4%)
Does not work (students) 4 (0.8%) 7 (2.9%)
Others 5 (1.0%) 6 (2.5%)
Psychiatric comorbidities, n (%)
Major depression 89 (18.3%) 41 (17.2%) 0.780
Panic disorder 67 (13.8%) 22 (9.2%) 0.100
Social anxiety 48 (9.9%) 16 (6.7%) 0.200
Phobias 38 (7.8%) 15 (6.3%) 0.550
Obsessive-compulsive disorder 18 (3.7%) 9 (3.8%) 0.867
Others 94 (19.3%) 41 (17.2%) 0.542
Medical comorbidities, n (%)
Chronic pain 230 (47.3%) 78 (32.6%) <0.001
Gastrointestinal disease 97 (20.0%) 53 (22.2%) 0.552
Cardiovascular disease 48 (9.9%) 24 (10.0%) 0.889
Metabolic disease 25 (5.1%) 21 (8.8%) 0.084
Genitourinary disease 26 (5.6%) 8 (3.4%) 0.312
Others 86 (17.7%) 43 (18.0%) 0.996
SSRI distribution by drug, n (%)
Paroxetine 177 (36.4) 57 (23.8) 0.001
Escitalopram 98 (20.2) 49 (20.5) 0.994
Sertraline 60 (12.3) 42 (17.6) 0.160
Mirtazapine 67 (13.8) 31 (13.0) 0.852
Table 1 Demographic and baseline clinical characteristics
of patients (Continued)
Citalopram 52 (10.7) 21 (8.8) 0.596
Fluoxetine 39 (8.0) 39 (16.3) 0.007
Benzodiazepine use
Users, n (%) 405 (83.3) 211 (88.3) 0.177
Mean (SD) # drugs 0.98 (0.58) 1.06 (0.56) 0.151
Clinical variables, mean (SD)
HAM-A scale score 27.2 (6.6) 25.7 (7.2) 0.015
MADRS scale score 23.6 (6.9) 21.7 (7.5) 0.001
CGI-I 4.2 (0.8) 4.0 (0.8) 0.001
SD standard deviation; CI confidence interval; HAM-A Hamilton Anxiety Rating
Scale; MADRS Montgomery-Asberg Depression Rating Scale; CGI-I Clinical
Global Impression-Improvement scale.
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Pharmacological treatment
The use of pharmacological resources is detailed in
Table 3. The utilization pattern of anxiolytic drugs
during the study was determined by the following pro-
portions at pregabalin vs. UC group: alprazolam (28.0%
vs. 20.9%), paroxetine (24.9% vs. 25.9%), escitalopram
(20.0% vs. 18.4%), lorazepam (19.1% vs. 21.8%), and di-
azepam (11.9% vs. 10.9%) as the most commonly used
benzodiazepines/SSRI for the treatment of GAD patients
with partial response to SSRI in routine medical practice
(Table 3). Drugs used by less than 3% of patients are not
shown. Pregabalin doses used in the study were within
the recommended therapeutic range (75 to 600 mg/day)
for this drug: mean (standard deviation) 186.2 (106.5)
mg, for a mean duration of treatment of 5.3 (1.5)
months (range: 0.1 to 6.1 months). During the study,
therapeutic consequences elected by physicians in GAD
patients with partial response to SSRI shown a trend to-
wards a 1/3 reduction both in benzodiazepines and SSRI
drugs independently of the considered treatment for re-
placement (pregabalin or other drugs).
Non-pharmacological health-care utilization
Table 4 shows the average non-pharmacological health
resources utilization at baseline and final visits of the
study as well as its change from baseline. Patients under
usual care have shown non-significant changes in non-
pharmacological treatment use relative to study initiation,
including psychosocial therapies, cognitive-behavioral ther-
apies, supportive groups, and relaxation sessions. In the
pregabalin group, only slightly higher non-pharmacological
utilization was detected for psychosocial therapy and sup-
portive group sessions (p < 0.05 in both). Mean medical
visits, overall and by type, as well as the number of hospital-
izations are shown in Table 4. After 6 months of study, the
reduction in the number of all medical visits reflected
significant reductions both in adjunctive therapy with
Figure 1 Mean (95% confidence interval) reduction in clinical variables (HAM-A, MADRS, CGI-I) after 6 months of study in pregabalin
and usual care groups.
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for baseline differences, the pregabalin-treated group
showed non-significantly greater reductions in pri-
mary care, emergency, and psychologist visits. On the
other hand, the usual care group showed slightly
higher reduction in psychiatrist number of visits (−1.3
vs. −1.9; p = 0.113). The number of hospitalizations
was similarly reduced in both groups after 6 months: −0.10
in the pregabalin-group vs. −0.09 in the UC group
(p = 0.501).Figure 2 Adjusted mean reduction in the raw score of 14 individual i
*p < 0.05; **p < 0.01; ***p < 0.001.Direct costs
Direct costs were obtained by multiplying the unit costs
by the total health-care resources used in each treatment
group (Table 4). The mean direct total cost at the initi-
ation of therapy was significantly different between the
two groups of patients: €2,177 ± 1,839 for pregabalin vs.
€1,724 ± 2,059 for UC group (p < 0.001). This was,
mainly, because of a higher baseline mean cost of med-
ical visits in the pregabalin group (€1,210 ± 1,253 vs.
€936 ± 1,136, p < 0.001) which was the main componenttems of HAM-A after 6 months of study, by treatment group.
Table 2 MOS-sleep and EQ-5D questionnaire scores by treatment group
Pregabalin Usual care p between
groupsN = 486 N = 239
Baseline Final Change (95% CI) Baseline Final Change (95% CI) Baseline Finala
MOS-sleep scale, mean (SD)
Sleep disturbance (0–100) 58.1 (18.9) 27.1 (17.5) −29.3 (−31.1, −27.4)** 50.1 (20.7) 32.0 (21.2) −22.4 (−24.9, −19.9)** <0.001 <0.001
Snoring while sleep (0–100) 32.5 (29.0) 23.9 (26.0) −7.1 (−9.0, −5.2)** 30.2 (30.3) 24.7 (26.9) −4.8 (−7.4, −2.2)** 0.175 0.142
Awakening short of breath
(0–100)
39.9 (22.8) 17.7 (19.6) −20.3 (−22.2, −18.4)** 30.6 (23.9) 20.9 (22.9) −13.2 (−15.7, −10.6)** <0.001 <0.001
Optimal sleep (0–1) 0.19 (0.39) 0.65 (0.48) 0.46 (0.41, 0.51)** 0.26 (0.44) 0.61 (0.49) 0.41 (0.34, 0.48)** <0.050 0.268
Sleep quality (0–100) 28.3 (19.7) 61.3 (24.0) 31.1 (28.7, 33.5)** 35.7 (22.6) 55.1 (26.1) 22.8 (19.5, 26.1)** <0.001 <0.001
Daytime sleepiness (0–100) 38.6 (18.6) 21.6 (15.9) −16.0 (−17.6, −14.4)** 33.7 (19.3) 23.6 (18.5) −12.5 (−14.6, −10.3)** <0.001 0.006
Sleep hours per night (0–24) 5.53 (1.25) 6.91 (1.05) 1.27 (1.16, 1.38)** 5.95 (1.53) 6.91 (1.13) 1.14 (0.98, 1.31)** <0.001 0.170
General index sleep problems
(0–100)
55.0 (15.0) 27.0 (16.0) −26.4 (−28.1, −24.7)** 47.5 (16.8) 31.2 (19.1) −19.6 (−22.0, −17.3)** <0.001 <0.001
EQ-5D questionnaireb
Mobility 1.40 (0.50) 1.22 (0.44) −0.17 (−0.21, −0.13)* 1.29 (0.50) 1.17 (0.39) −0.17 (−0.22, −0.12)* 0.002 0.922
[39.4] [21.4] [27.1] [17.0] <0.001 0.375
Personal care 1.26 (0.45) 1.09 (0.29) −0.15 (−0.18, −0.12)* 1.19 (0.42) 1.12 (0.36) −0.12 (−0.16, −0.08)* 0.027 0.174
[26.0] [8.7] [18.4] [10.3] 0.032 0.196
Activities of daily living 2.14 (0.50) 1.56 (0.54) −0.52 (−0.58, −0.47)** 1.88 (0.49) 1.59 (0.58) −0.43 (−0.51, −0.36)** <0.001 0.047
[93.3] [53.3] [81.5] [54.7] <0.001 0.221
Pain/discomfort 2.11 (0.63) 1.57 (0.60) −0.51 (−0.56, −0.45)** 1.90 (0.63) 1.58 (0.62) −0.42 (−0.49, −0.35)** <0.001 0.043
[85.4] [51.5] [74.6] [50.8] <0.001 0.789
Anxiety/depression 2.52 (0.52) 1.54 (0.58) −0.94 (−1.00, −0.64)** 2.37 (0.57) 1.75 (0.61) −0.72 (−0.80, −0.64)** 0.001 <0.001
[98.8] [50.0] [95.8] [65.7] 0.002 <0.001
Self-valuation quality of life
(EQ-VAS; 0–100)
42.7 (15.5) 70.0 (17.3) 26.4 (24.7, 28.1)** 48.9 (15.7) 65.5 (18.3) 19.4 (17.1, 21.6)** <0.001 <0.001
Health status (utility index; 0–1) 0.40 (0.30) 0.78 (0.25) 0.36 (0.34, 0.38)** 0.53 (0.31) 0.75 (0.28) 0.29 (0.26, 0.33)** <0.001 <0.001
Values are expressed as mean (SD, standard deviation) or 95% confidence intervals (CI) unless otherwise stated.
aComparison of the change from baseline between the two groups adjusted by baseline values and sex and age.
bThe percentage of patients who still have problems (sum of categories 2 and 3) for each EQ-5D component are expressed within brackets.
p < 0.05, *p < 0.01, **p < 0.001 vs. baseline values.
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pregabalin group and 54% in the UC group.
Health-care costs were significantly reduced in both
cohorts yielding to similar 6-month costs; €1,565 ± 1,555
pregabalin and €1,406 ± 1,611 UC (p = 0.777). At the 6-
month visit, medical visits were still responsible for most
of the costs, but in a lower total percentage, representing
now only the 30% and 41% of the total cost in the prega-
balin and UC groups, respectively. The previously de-
scribed reduction in the number of medical visits in
both groups resulted in a significant reduction in the
costs associated to this health resource (€736 in the
pregabalin group and €356 in the UC group, p < 0.001 in
both groups), although mean adjusted pharmacologic
cost increased significantly in both groups of patients:
€280 in the pregabalin group and €38 in the UC group
(p < 0.001).The overall significant increase in the drug costs in the
pregabalin group of patients was compensated by signifi-
cant reductions in the number of visits and almost sig-
nificant in the number of hospitalizations in this group
of patients. Overall, these cost components resulted in a
similarly meaningful reduction of total health-care costs
both in adjunctive therapy with pregabalin and UC
groups: −478 vs. −446 (p = 0.777).
Discussion
In this paper, we report the significant improvement in
symptoms observed in GAD patients with partial re-
sponse to previous SSRI treatment when changed to ad-
junctive therapy with pregabalin in comparison with
usual care. Under current European guidelines, it is rec-
ommended that pregabalin, SSRIs, and SNRIs are used
as primary therapeutic options for the treatment of
Figure 3 Adjusted mean reduction in patient disability reported WHO-DAS II components after 6 months of study in pregabalin and
usual care groups. *p < 0.05; **p < 0.01; ***p < 0.001 between groups adjusted by age, sex, and baseline values.
Table 3 Main pharmacological treatments during the study with pregabalin or usual care therapy
Pharmacological
treatment
Pregabalin Usual care p (percentage
between
groups)
N = 486 N = 239
n (%) Dose Duration n (%) Dose Duration
mg/day (SD) months (SD) mg/day (SD) months (SD)
Benzodiazepines 326 (67.1) 162 (67.8) 0.867
Alprazolam 136 (28.0) 2.0 (1.3) 4.7 (2.0) 50 (20.9) 2.0 (1.4) 4.7 (1.9)
Diazepam 58 (11.9) 10.2 (7.1) 4.4 (2.0) 26 (10.9) 12.9 (6.8) 5.1 (1.7)
Lorazepam 93 (19.1) 2.6 (1.6) 4.7 (1.9) 52 (21.8) 1.2 (1.3) 4.8 (1.8)
Clorazepate dipotassium 39 (8.0) 23.3 (19.7) 4.4 (2.0) 26 (10.9) 15.9 (9.5) 4.9 (1.5)
Bromazepam 21 (4.3) 5.7 (6.4) 4.8 (1.9) 10 (4.2) 4.7 (2.1) 4.9 (1.5)
Clonazepam 16 (3.3) 9.0 (19.2) 4.1 (2.4) 11 (4.6) 12.6 (13.0) 4.5 (2.3)
Others 75 (15.4) - - 50 (20.9) - -
SSRI 331 (68.1) 162 (67.8) 0.933
Paroxetine 121 (24.9) 24.5 (8.9) 5.0 (1.9) 62 (25.9) 25.6 (10.8) 5.3 (1.6)
Escitalopram oxalate 97 (20.0) 18.2 (6.4) 5.2 (1.5) 44 (18.4) 14.9 (4.7) 4.5 (1.8)
Mirtazapine 63 (13.0) 26.1 (9.0) 4.8 (1.8) 29 (12.1) 26.0 (6.3) 5.0 (1.3)
Sertraline 42 (8.6) 111.9 (53.8) 5.6 (1.2) 20 (8.4) 103.9 (58.4) 5.5 (1.3)
Citalopram 29 (6.0) 24.4 (9.2) 4.8 (1.6) 15 (6.3) 23.9 (8.4) 5.3 (1.1)
Fluoxetine 17 (3.5) 27.7 (12.0) 4.5 (2.3) 18 (7.5) 27.0 (9.2) 4.7 (2.2)
Others 12 (2.5) - - 13 (5.5) - -
SNRI 106 (21.8) 39 (16.3) 0.093
Venlafaxine hydrochloride 61 (12.6) 155.4 (53.9) 5.3 (1.4) 26 (10.9) 148.0 (47.3) 5.6 (1.0)
Duloxetine 48 (9.9) 68.7 (26.9) 5.5 (1.7) 13 (5.4) 61.8 (21.0) 4.9 (1.6)
SSRI selective serotonin reuptake inhibitors, SNRI serotonin-norepinephrine reuptake inhibitors.
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Table 4 Health resources utilization and direct costs (€) by treatment group
Pregabalin Usual care p between
groups
N = 486 N = 239
Baseline Final Change (95% CI) Baseline Final Change (95% CI) Baseline Finala
Resources
Non-pharmacological treatmentb
Psychosocial therapy 0.1 (0.4) 0.1 (0.7) 0.07 (0.01, 0.13)* 0.1 (0.6) 0.1 (0.5) 0.01 (−0.06, 0.09) 0.122 0.226
Cognitive-behavioral therapies 0.4 (1.0) 0.3 (1.0) 0.14 (0.00, 0.30) 0.3 (1.0) 0.5 (2.0) 0.20 (0.00, 0.41) 0.441 0.642
Supportive groups 0.1 (0.4) 0.2 (0.9) 0.10 (0.01, 0.18)* 0.1 (0.7) 0.2 (0.9) 0.06 (−0.06, 0,18) 0.476 0.588
Relaxation 0.5 (1.3) 0.6 (1.7) 0.09 (−0.06, 0.25) 0.5 (1.5) 0.7 (2.3) 0.13 (−0.09, 0.34) 0.639 0.792
Number of medical visitsc
Primary care 11.9 (13.9) 2.4 (3.7) −9.0 (−9.5, −8.5)*** 10.4 (12.8) 2.7 (5.5) −8.3 (−9.0, −7.6)*** 0.015 0.100
Emergency department 4.6 (8.0) 0.7 (7.6) −3.9 (−4.6, −3.2)*** 3.7 (6.9) 0.3 (0.8) −3.8 (−4.8, −2.7)*** 0.078 0.833
Psychologist 3.0 (7.2) 1.8 (4.6) −1.0 (−1.5, −0.5)*** 2.8 (9.4) 2.4 (5.2) −0.9 (−1.6, −0.2)** 0.048 0.860
Psychiatrist 5.9 (6.4) 3.9 (3.7) −1.3 (−1.7, −1.0)*** 3.9 (5.1) 3.0 (2.7) −1.9 (−2.4, −1.3)*** <0.001 0.113
Total medical visits 25.4 (22.0) 8.7 (11.2) −15.2 (−16.3, −14.0)*** 20.7 (20.1) 7.6 (8.4) −14.9 (−16.6, −13.2)*** 0.001 0.754
Number of hospitalizations 0.2 (0.9) 0.0 (0.1) −0.10 (−0.11, −0.09)*** 0.1 (0.6) 0.0 (0.1) −0.09 (−0.10, −0.08)*** 0.134 0.501
Costs (euros year 2009):
Total costs 2,177 (1,839) 1,565 (1,555) −478 (−619, −338)*** 1,724 (2,059) 1,406 (1,611) −446 (−635, −257)*** <0.001 0.777
Drugs 254 (304) 534 (281) 296 (272, 319)*** 204 (256) 241 (228) 27 (−5, 58) 0.001 <0.001
Non-pharmacological treatment 202 (359) 274 (577) 86 (23, 148)** 191 (379) 282 (748) 88 (3, 172)* 0.115 0.969
Medical visits 1,210 (1,253) 474 (1,002) −660 (−753, −567)*** 936 (1,136) 580 (893) −471 (−596, −345)*** <0.001 0.013
Hospitalization 40 (254) 2 (21) −28 (−35, −21)*** 14 (149) 9 (109) −17 (−26, −8)** 0.134 0.056
Values are expressed as mean (SD, standard deviation) or 95% confidence intervals (CI) unless otherwise stated.
aComparison of the change from baseline between the two groups adjusted by baseline values and sex and age.
bNumber of sessions per month.
cIn a 6-month period.
*p < 0.05, **p < 0.01, ***p < 0.001 vs. baseline values.
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ish Ministry of Health [17] that benzodiazepines can be
used for 2–4 weeks to prevent adverse events in the
medium to long term as well as afflictive withdrawal
symptomatology [12-15]. Under this premise, the under-
standing of current therapeutic options and their opti-
mal utilization, under an efficient cost-consequence
perspective, highlights the need for an appropriate esti-
mation of economic consequences in the management
of GAD patients. This estimation must take into account
overall health-care resource and drug acquisition costs,
especially when partial and/or partial responses to initial
therapeutic options have been demonstrated [6].
To the best of our knowledge, our study presents the
first analysis of clinical and economic consequences in
GAD patients with partial response to previous treat-
ment with SSRIs in routine medical care conditions. Our
data adds support to previous results on the overall eco-
nomic evaluation of different therapeutic options for the
treatment of GAD patients in Spain [42,43]. Further-
more, this study evaluates the effective use of pregabalin
as a treatment alternative when refractory outcomes
have been demonstrated, i.e., with benzodiazepines [44].In our study, as a result of the primary endpoint, we
have observed that the addition of pregabalin to usual
care leads to a significant reduction in anxiety and de-
pression symptoms in comparison to usual care (p <
0.0001, in both cases). These reductions have been
shown to be above or equal to the 50% of the baseline
values in case of pregabalin. Significantly, it has to be
stated that no differences in the anxiety and depression
reductions were detected between sexes, thus dismissing
a differential trend in terms of this fact. These trends are
in accordance with a meta-analysis of eight published
trials that evaluates the efficacy and tolerability of prega-
balin in the treatment of GAD [45]. In this study, prega-
balin treatment resulted in an overall lowered Hamilton
Anxiety Rating Scale for anxiety scores within 1 week.
The observed decrease in anxiety scores of our patients
also confirms the recent findings by Rickels et al. that re-
ported a significantly greater benefit for adjunctive preg-
abalin compared with placebo [46]. This randomized
clinical trial of GAD patients with partial response to
SSRI or SNRI described a mean reduction in HAM-A
total score (−7.6 for pregabalin vs. −6.4 for placebo (p <
0.05)) during the 8 weeks of combination treatment [46].
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study, the confirmed reductions sustain the initial obser-
vations of a pooled post hoc analysis that reflected prega-
balin reduced associated symptoms of depression despite
its dose [47]. In agreement with our results, a recent
open-label trial [48] found statistically significant reduc-
tions (p < 0.001) in depression in older patients with
GAD and comorbid depression from the fourth week of
treatment. Global trends in amelioration of anxiety and
depression outcomes were confirmed in our study by
the significant change in the patient-reported Clinical
Global Impression scale that benefits adjuvant pregaba-
lin in GAD patients with partial response to SSRI with
respect to UC (p < 0.005).
Comparable trends were detected for pregabalin adju-
vant therapy in patient-reported outcomes concerning
disability state and sleep quality. Significant differences
in the reduction of all disability WHO-DAS II domains
were probed at the end of the study and were found to
favor pregabalin therapy, both in employed and un-
employed patients (p < 0.0001, in both cases). Improve-
ments were substantial in cases of pregabalin treatment,
with sleep amelioration and reduction in disability being
of a magnitude above or equal to the 50% of the baseline
values. The beneficial effects of pregabalin in disability
status have been previously demonstrated in neuropathic
pain patients evaluated through Sheehan Disability In-
ventory scale [49]. Besides, all items considered in the
MOS-sleep scale, including average number of hours
slept per day, presented significant higher improvements
after the 6 months of the study for patients receiving
pregabalin in comparison to UC. However, the only ex-
ceptions of this were the snoring score and the optimal
sleep score that were lower with pregabalin but not sig-
nificant. As suggested by a previous pooled analysis of
seven studies of pregabalin therapy in GAD patients,
53% of the effect of pregabalin on sleep disturbance was
due to a direct drug effect and 47% was due to an indir-
ect effect mediated through prior reduction in anxiety
symptom severity [50].
Improvement in sleep outcomes and reduction of day-
time sleepiness in GAD patients treated with pregabalin
has been also demonstrated in correlation with improve-
ment in quality of life, according to subjective global
measures, as well as with amelioration in functional im-
pairment [50]. In our study sample of GAD patients with
partial response to SSRI, pregabalin adjuvant therapy
was associated with a differential 36% improved benefits
in self-valuation quality of life (EQ-5D visual analogue
scale) and social tariff derived from such instrument in
comparison with usual care. Furthermore, improvements
in sleep and disability, together with major reductions in
GAD symptoms, were translated to better outcomes in
some dimensions of quality of life as described by thepatient. Thus, in addition to anxiety/depression, patients
receiving pregabalin also showed better activities of daily
living and pain/discomfort in the EQ-5D questionnaire
than subjects receiving usual care. These findings are co-
herent with previous publication [51].
Concerning therapeutic aspects and despite the fact
that all the included patients in our analysis were partial
responders for SSRIs, it should be noted than more than
2/3 of the sample were still taking benzodiazepines dur-
ing the last 6 months. This observation occurred inde-
pendently of the pregabalin adjuvant incorporation, or
lack thereof, in the usual care group. On the other hand,
adding pregabalin was correlated with a near 1/3 of re-
duction in benzodiazepines and SSRIs prescribed by
physicians. It is important to consider that under this
observation, psychiatrists could fulfil the recommended
therapeutic goals related with benzodiazepines early by
initiating GAD therapy with pregabalin in SSRI partial
responders [52].
When comparing the results of our study with a previ-
ous Spanish economic evaluation of the annual cost of
GAD, confirmed by DSM-IV criteria, the mean cost of
GAD in primary care was estimated at €686, from which
drug costs represented 59% of the total costs [53]. This
economic cost is higher than our present estimate where
the pharmaceutical cost represents 34% of the overall
costs in the pregabalin group and 17% in the usual care
group. Overall, in our GAD patients sample with partial
response to previous SSRIs, the mean total costs over
1 year decreased by €478 in the pregabalin group and by
€446 in the usual care group. Although the pharmaco-
logical treatment costs per year were higher after prega-
balin adjuvant incorporation (€534 vs. €241 in UC, p <
0.001), significant lower costs were detected for medical
visits (€474 vs. €580 in UC, p = 0.013) and an almost
significant lower cost associated with hospitalizations
(€2 vs. €9 in UC, p = 0.056). This framework results in a
similar global health-care resource costs in both groups:
€1,565 in the pregabalin group and €1,406 in the UC
group (p = 0.777).
Main weaknesses of our work should also be noted.
First, although some studies show that indirect costs
resulting from associated loss of productivity double the
usual direct costs of GAD [54,55], our study did not
consider the indirect expenses associated with neither
treatment nor the out-of-pocket costs as it was per-
formed directly from the perspective of the National
Health System. Second, the non-interventional design of
the original data, the ADAN study, does not allow for
any inference of direct causality between GAD treatment
options and full costs of the associated patient’s manage-
ment. While this may be venturesome in terms of
conclusive interpretations, our approach, based on real-
world data, allows for health decision makers from the
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conclusions regarding the estimation of health-care re-
source utilization and its associated direct costs. Finally,
the total study sample size included could be considered
relevant in comparison with previous comparative cost
analysis performed within the group of Spanish patients
with refractory GAD [10,56].Conclusions
To conclude, our results suggested that initiating ther-
apy with pregabalin in SSRI partial responders benefits
anxiety and depression outcomes and does not imply
significant increased direct costs when compared with
the usual care treatment in a routine clinical practice
basis. Moreover, the use of adjuvant pregabalin is associ-
ated with a lower use both of benzodiazepines and SSRIs
as concomitant anxiolytic drugs. In spite of the limita-
tions considered, the study showed that the significant
higher pharmacological acquisition costs of pregabalin
was compensated by improved clinical outcomes and
higher reductions in non-pharmacological costs. Such a
reduction in costs, such as medical visits and hospitali-
zations, could infer improved reductions in the overall
management of GAD patients with partial response to
SSRI from the National Health System perspective.Abbreviations
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